• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Empagliflozin reduces the risk of long-term renal effects in type 2 diabetes

byShayna BejaimalandShaidah Deghan, MSc. MD
July 28, 2016
in Chronic Disease, Endocrinology, Nephrology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with type 2 diabetes and an estimated glomerular filtration (eGFR) rate of ≥ 30 mL per minute per 1.73 m2 of body-surface area that received empagliflozin, there was reduced incidence of new or worsening nephropathy, less incidence of doubling of creatinine and less initiation of renal-replacement therapy.

2. Adverse event rates were similar in the empagliflozin group to that reported in the overall trial population.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The EMPA-REG OUTCOME trial demonstrated that empagliflozin reduced the risk of major cardiovascular events in patients with type 2 diabetes at high risk of cardiovascular events. This subsequent pre-specified analysis aims to determine the long-term effects of empagliflozin on the kidney.

In the empagliflozin group there was significantly less incident or worsening nephropathy, less incidence of doubling of creatinine and less initiation of renal-replacement therapy, as compared to placebo. There was no statistical difference between-group difference in the rate of incident albuminuria. Adverse event rates in patients with impaired kidney function on empagliflozin were similar to that reported in the overall trial population. Strengths of this study include it being a large, multi-centre, placebo-controlled double-blinded trial. It also studied the important outcome of renal replacement therapy. However, this trial had low enrollment of black patients and thus impacts the generalizability to this important patient population.

Click to read the study, published today in NEJM

RELATED REPORTS

#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes

Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss

Semaglutide improves walking ability in patients with peripheral artery disease and type 2 diabetes

Relevant Reading: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

In-Depth [randomized controlled trial]: The EMPA-REG OUTCOME trial was a multi-centre, randomized, double-blind, placebo-controlled trial. The study population included patients with type 2 diabetes, established cardiovascular disease and eGFR of at least 30mL/min/1.73 m2 of body-surface area determined by the MDRD eGFR equation. Patients were then randomly assigned to receive empagliflozin (10 mg or 25 mg daily) or once daily placebo. This separate analysis looked at microvascular outcomes. Specifically, incident or worsening nephropathy (defined as progression to macroalbuminuria), doubling of the serum creatinine and a decrease of eGFR to ≤ 45 mL/min/1.73 m2 of body-surface area, initiation of renal-replacement therapy or death from renal disease. Statistical analysis included a modified intention-to-treat approach with Cox proportional hazards to assess between group differences in risk.

The proportion of individuals that had an incident or worsening nephropathy were 12.7% in the empagliflozin group and 18.8% in the placebo group (HR 0.61; 95%CI 0.53-0.70, p < 0.001). Doubling of creatinine level occurred in 1.5% of those on empagliflozin and 2.6% in the placebo group, relative risk reduction of 44%. There was also a significant decrease in initiation of renal replacement therapy, 0.3% in the empagliflozin group and 0.6% in the placebo group, a 55% relative risk reduction. There was no significant difference in incident albuminuria. Adverse events in patients with baseline impaired kidney function and on empagliflozin were similar to those reported in the overall trial population.

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: diabetes mellitussglt2 inhibitors
Previous Post

Anti-IL-17A therapy linked to sustained improvement in plaque psoriasis: The UNCOVER trials

Next Post

Liraglutide associated with lower incidence of death from CV causes in type 2 diabetics

RelatedReports

#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes
StudyGraphics

#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes

July 7, 2025
Sleep duration inversely related to childhood type 2 diabetes risk makers
Cardiology

Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss

June 23, 2025
Increased number of daily steps linked with decreased mortality in older women
Chronic Disease

Semaglutide improves walking ability in patients with peripheral artery disease and type 2 diabetes

May 29, 2025
Glucagon-like Peptide-1 Receptor Agonists and Lower Depression Risk in Older Adults with Diabetes
StudyGraphics

Glucagon-like Peptide-1 Receptor Agonists and Lower Depression Risk in Older Adults with Diabetes

March 13, 2025
Next Post
Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors

Liraglutide associated with lower incidence of death from CV causes in type 2 diabetics

Image-guided percutaneous drainage of pericardial effusions is safe and effective

Point-of-care hemostatic test during TAVR procedure may help predict negative outcomes

Increased complications associated with emergent repeat cesarean

Later physician rounding improves satisfaction of postpartum women

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
  • Mazdutide significantly reduces weight in adults with overweight or obesity
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.